Preface

For oncologists managing patients with lung cancer last few years have been historic. First there was an approval of anaplastic lymphoma kinase (ALK) inhibitor crizotinib in 2013, followed by recognition of benefit from lung cancer screening with a low dose CT. Recently, there was a discovery and development of 2^nd generation ALK inhibitors, and finally an approval of nivolumab for patients with squamous cell lung cancer (1-4). On a radiation therapy side stereotactic body radiation therapy (SBRT) has emerged as an effective modality with high local control and excellent safety profile for patients with early stage lung cancer.